|
|
||||||||
/
mice and the
effect of docosahexaenoic acid
Departments of 1 Medicine and 3 Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215; and 2 Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232
| |
ABSTRACT |
|---|
|
|
|---|
The mechanism by which
Pseudomonas causes excessive inflammation in the cystic
fibrosis lung is unclear. We have reported that arachidonic
acid is increased and docosahexaenoic acid (DHA) decreased in lung,
pancreas, and ileum from cftr
/
mice. Oral
DHA corrected this defect and reversed the pathology. To determine
which mediators regulate inflammation in lungs from cftr
/
mice and whether inhibition occurs
with DHA, cftr
/
and wild-type (WT) mice were
exposed to aerosolized Pseudomonas lipopolysaccharide (LPS).
After 2 days of LPS, tumor necrosis factor-
(TNF-
), macrophage
inflammatory protein-2, and KC levels in bronchoalveolar lavage fluid
were increased in cftr
/
compared with WT
mice and not suppressed by pretreatment with oral DHA.
Neutrophil levels were not different between
cftr
/
and WT mice. After 3 days of
aerosolized LPS, neutrophil concentration, TNF-
, and the eicosanoids
6-keto-PGF1
, PGF2
, PGE2, and
thromboxane B2 were all increased in bronchoalveolar lavage fluid from cftr
/
mice compared with WT
controls. Oral DHA had no significant effect on TNF-
levels in
cftr
/
mice. In contrast, neutrophils and
eicosanoids were decreased in cftr
/
but not
in WT mice treated with DHA, indicating that the effects of DHA on
these inflammatory parameters may be related to correction of the
membrane lipid defect.
cystic fibrosis; cytokines; neutrophils; Pseudomonas
| |
INTRODUCTION |
|---|
|
|
|---|
CYSTIC FIBROSIS (CF) IS AN autosomal recessive disorder caused by mutations of the gene encoding the CF transmembrane conductance regulator (CFTR) (23). Patients with CF express a typical phenotype characterized by pancreatic insufficiency, ileal hypertrophy, and recurrent pulmonary infections that ultimately lead to pulmonary failure and death. Pulmonary disease in CF is characterized by excessive inflammation in response to infection by Pseudomonas aeruginosa. It has been recently reported that, in the absence of detectable lung infection, the bronchoalveolar lavage (BAL) fluid of CF patients contains increased levels of proinflammatory cytokines and neutrophils (2, 18, 20). In addition, interleukin (IL)-8 levels in BAL fluid from children with CF are significantly higher than those in non-CF children with bacterial infection of the lower airways (21). Furthermore, basal secretion of IL-6 and IL-8 was higher in human CF bronchial gland cells than in human gland cells obtained from normal individuals (16, 26). These data suggest that CFTR mutations may lead to an excessive inflammatory response in the lung.
The mechanism responsible for this enhanced inflammatory response has
been difficult to study in vivo because
cftr
/
mice [University of North Carolina
(UNC) knockouts] show little spontaneous lung inflammation. To
circumvent this problem, a model has been established whereby
instillation of agarose beads coated with Pseudomonas into
the lungs of S489X cftr
/
mice has been shown
to result in increased inflammation and mortality compared with that
observed in wild-type (WT) mice (13, 14). However, in
those studies, the mortality rate was significant in both control and
cftr
/
mice. This could be due, at least in
part, to airway obstruction after instillation of the agarose beads.
Our laboratory (11) has recently reported the presence of
a membrane lipid defect in lung, pancreas, and ileum from
cftr
/
mice characterized by an increase in
phospholipid-bound arachidonic acid and a decrease in
phospholipid-bound docosahexaenoic acid (DHA). Correction of this fatty
acid defect with high doses of oral DHA led to reversal of the
pathological manifestations of CF in pancreas and ileum. However,
cftr
/
mice do not express spontaneous
pulmonary disease. Therefore, an animal model was established whereby
mice were exposed to aerosolized Pseudomonas
lipopolysaccharide (LPS) once a day for 3 days to mimic persistent
infection in CF. This demonstrated a twofold increase in neutrophil
concentration in BAL fluid from cftr
/
mice
compared with that observed in WT mice (11).
The objective of this study was to determine which specific
proinflammatory mediators may be responsible for the enhanced inflammatory response observed in lungs from
cftr
/
mice after exposure to
Pseudomonas LPS and whether oral DHA suppresses this
enhanced inflammatory response. Using this model, we demonstrate that
there is an increased neutrophil infiltration in lungs from cftr
/
mice compared with WT mice in response
to Pseudomonas LPS and that this neutrophil infiltration is
preceded by an increase in the production of tumor necrosis factor-
(TNF-
), macrophage inflammatory protein-2 (MIP-2), and KC. In
addition, the levels of the eicosanoids PGF1
(6-keto-PGF1
), PGF2
, PGE2, and thromboxane B2 (TxB2) were all increased in
BAL fluid from cftr
/
mice compared with
those in WT controls. Oral administration of DHA resulted in a
selective decrease in these eicosanoids in cftr
/
mice that was not observed in WT mice.
| |
METHODS |
|---|
|
|
|---|
Breeding of cftr
/
mice and oral
administration of DHA.
Experiments were approved by the Beth Israel Deaconess Medical Center
Animal Care Committee. A breeding colony was established with UNC
heterozygous cftr
/
exon 10 knockout mice
(Jackson Laboratories, Bar Harbor, ME). Tail clip samples of 14-day-old
mice were processed for analysis of genotype (28). Both WT
(C57 as well as UNC cftr+/+ mice) and
cftr
/
mice were weaned at 23 days of age.
After weaning, age-matched WT and cftr
/
mice
were placed on water and Peptamen (Nestle Clinical Nutrition, Deerfield, IL) ad libitum until 30 days of age and then continued for 7 days with Peptamen or 40 mg/day of DHA (Sigma Chemical, St. Louis, MO)
prepared as a stable emulsion in Peptamen. The volume of Peptamen
administered was measured on a daily basis with specific feeders.
Analysis of lung inflammation.
Weight-matched WT and cftr
/
mice, with and
without pretreatment with oral DHA, were given a single dose of
aerosolized Pseudomonas LPS (10 mg/15 g body wt, unless
indicated) over 15 min once a day for up to 3 days.
Pseudomonas LPS (Sigma Chemical) was sonicated in saline and
administered at 20 lb./in.2 with a nebulizer connected to a
compressed air tank, which was connected to a large plastic container
with vent holes into which the animals were placed. It should be noted
that WT mice generally weigh more than age-matched
cftr
/
mice, and thus weight-matched animals
were used in experiments. All animals were between 30 and 37 days of age.
, MIP-2, KC,
and IL-1
levels in BAL fluid were determined with commercially
available EIA kits (R&D Systems, Minneapolis, MN) with lower limits of
detection of 10, 5, 15, and 5 pg/ml, respectively. PGF1
(6-keto-PGF1
), PGF2
, PGE2,
and TxB2 were quantified by using stable isotope dilution
methodology employing gas chromatography-negative ion chemical
ionization mass spectrometry (7).
Statistical analysis. The differences between the means were evaluated by using Student's t-test comparing two conditions and ANOVA for comparing three or more variables.
| |
RESULTS |
|---|
|
|
|---|
Selection of Pseudomonas LPS dose.
To determine the optimum dose of LPS, aerosolized
Pseudomonas LPS was administered at different doses to WT
mice, and, after 3 h, neutrophil, TNF-
, and KC levels in BAL
fluid were measured (Fig. 1).
Neutrophils, TNF-
, and KC were undetectable in BAL fluid of mice
treated with LPS-free saline. After administration of up to 5 mg LPS/15
g body wt, neutrophil concentration and TNF-
in BAL fluid increased
linearly (P < 0.05 comparing 0, 1, and 5 mg LPS by
ANOVA), with no further significant increase at 10 mg LPS/15 g body wt.
KC levels were also increased in BAL fluid in a dose-dependent manner,
with the exception that the increase was statistically different
(P < 0.05) among all values examined from 0 to 10 mg
LPS/15 g body wt. Because 10 mg LPS/15 g body wt resulted in maximal
neutrophil levels, this dose was used for subsequent experiments. Also,
because there was no significant difference in the results obtained
from UNC cftr+/+ mice compared with C57 WT mice
either for a single dose of aerosolized LPS or after 2 or 3 days of
repeated daily administration of aerosolized Pseudomonas LPS
(data not shown), the latter were used for subsequent experiments.
|
Repeated administration of Pseudomonas LPS.
The effects of repeated administration of aerosolized
Pseudomonas LPS on cytokine, chemokine, and neutrophil
levels were examined in WT mice. TNF-
, MIP-2, and KC levels in BAL
fluid peaked on day 1, 3 h after the initial inhalation
(Fig. 2). On the next 2 days, levels of
these inflammatory mediators also peaked 3 h after LPS inhalation.
However, these levels were two- to threefold lower than peak levels
observed on day 1. IL-1
increased after 2 days of
aerosolized LPS exposure to only twice its level on day 1 with no further significant increase. In contrast, neutrophil concentration in BAL fluid increased slowly on day 1 relative to cytokine and chemokine levels, exhibiting a twofold
increase from day 1 to day 2. Neutrophil
concentration in BAL fluid remained relatively constant at these levels
on days 2 and 3, with the occurrence of small
spikes that coincided with the increase in cytokine levels. Neutrophils
were the predominant inflammatory cells with <3% lymphocytes and
macrophages identifiable by light microscopy (Fig.
3A). Neutrophils were present
throughout the air spaces, including both bronchi and alveoli.
|
|
Comparison of cytokine, chemokine, and neutrophil levels in
cftr
/
and WT mice after Pseudomonas
LPS-induced inflammation.
We then investigated whether levels of these inflammatory mediators
were different in cftr
/
compared with WT
mice. TNF-
, MIP-2, and KC levels in BAL fluid on day 2 were significantly higher (P < 0.05) in
cftr
/
mice than in WT mice (Fig.
4). IL-1
levels were low, with no significant differences between cftr
/
and WT
mice. Although a similar trend was observed after 3 days of aerosolized
Pseudomonas LPS, only TNF-
demonstrated a statistically significant difference (P < 0.05) in
cftr
/
compared with WT mice (Fig.
5).
|
|
Eicosanoid levels in cftr
/
and
WT mice after Pseudomonas LPS-induced
inflammation.
Eicosanoids were also examined in this model after administration
of aerosolized LPS for 3 days. 6-keto-PGF1
,
PGF2
, PGE2, and TxB2 levels were
significantly higher in BAL fluid from cftr
/
compared with WT mice (P < 0.05) (Fig.
6A). No significant
differences in LTB4 levels were observed between
cftr
/
and WT mice (Fig. 6B).
|
Effect of DHA pretreatment on Pseudomonas
LPS-induced inflammation.
Pretreatment of either cftr
/
or WT mice with
oral DHA had no effect on IL-1
after either 2 or 3 days of
aerosolized Pseudomonas LPS exposure (Figs. 4 and 5).
Similarly, DHA administration to WT or cftr
/
mice did not cause significant changes in MIP-2 or KC levels in BAL
fluid after 2 and 3 days of exposure to aerosolized LPS. WT mice
treated with oral DHA demonstrated a statistically significant decrease
in TNF-
levels (P < 0.05) after 2 and 3 days of
Pseudomonas LPS exposure compared with untreated WT mice
(Figs. 4 and 5). Although similar trends in TNF-
levels were
observed after DHA administration to cftr
/
mice, these changes were not statistically significant.
/
mice with oral DHA resulted in a
significant decrease in 6-keto-PGF1
, PGF2
, PGE2, and TxB2 levels in
BAL fluid (P < 0.05) (Fig. 6). These levels were
similar to those observed in WT animals either treated or not treated
with DHA. LTB4 levels were not significantly altered by DHA.
Cytokine production and neutrophil concentration in
BAL fluid.
To determine the relationship between cytokine levels and neutrophil
infiltration in cftr
/
and WT mice,
neutrophil concentration in BAL fluid was determined at different times
after LPS exposure. Neutrophil concentration in BAL fluid was
significantly increased in cftr
/
mice
compared with WT controls after exposure to aerosolized LPS for 3 days
(P = 0.004) (Fig. 7).
This is seen in the representative micrographs shown in Fig. 3. This
difference in neutrophil concentration between WT and
cftr
/
mice was not observed on day
2. Pretreatment of cftr
/
mice with oral
DHA suppressed the increase in neutrophil concentration observed on
day 3 to levels found in WT mice but had no effect on
neutrophil concentration on day 2. Pretreatment of WT mice with DHA did not have any significant effect on neutrophil
concentration in BAL fluid from WT mice on either day 2 or
3.
|
| |
DISCUSSION |
|---|
|
|
|---|
Because chronic exposure to Pseudomonas plays a major
role in the pathogenesis of CF-induced lung disease, we have examined the effects of repeated aerosolized Pseudomonas LPS exposure
on the genesis of lung inflammation in cftr
/
mice. This model has the advantage that the mortality rate is negligible in contrast to the 23% mortality rate observed in WT mice
after intratracheal instillation of Pseudomonas-coated
agarose beads (14). Using a different approach,
Thomas et al. (26a) have shown that intravenous
administration of LPS leads to a qualitative increase in the number of
neutrophils in the lung parenchyma of mice with the G551D mutation in
CFTR compared with WT control mice, although the air spaces were devoid
of inflammatory cells. Davidson et al. (8) examined the
effects of aerosolized Staphylococcus aureus and
Burkholderia cepacia given daily in low doses for up to 1 mo
to cftrm1HGU mice. In these animals, which
display a milder phenotype, a predominantly lymphoid infiltrate was
present in the lungs and was associated with goblet cell hyperplasia
and mucus retention. No mortality was observed. However, the pneumonia
observed in CF patients is characterized by a predominantly
neutrophilic infiltrate, and thus this model is not representative of
lung disease in CF patients. Our present model, which results in a
predominantly neutrophilic infiltrate, is more representative of lung
disease in humans, although alveoli tend to be less involved in humans
with CF. However, both our model as well as the
Pseudomonas-coated agarose bead model result in infiltration
of inflammatory cells in the upper airways as well as the alveoli
(13). Although important information can be learned from
LPS-stimulated inflammation, Pseudomonas factors in addition
to LPS are also likely to influence the host response and progression
to chronic infection in human CF, such as secreted toxins, proteases,
alginate, and other virulence factors.
The fact that an increase in neutrophil concentration in BAL fluid from
cftr
/
mice, compared with WT controls, was
observed after 3 but not after 2 days of aerosolized
Pseudomonas LPS exposure allowed us to attempt to
discriminate which inflammatory mediators may be responsible for this
excessive inflammatory response in cftr
/
mice. In cftr
/
mice, the increase in
neutrophils was preceded by a rise in TNF-
levels, which were
significantly increased above WT values after 2 and 3 days of
aerosolized Pseudomonas LPS. Although KC and MIP-2 levels on
days 2 and 3 were higher in
cftr
/
mice than in WT, statistical
significance was reached only on day 2. These data suggest
that TNF-
, MIP-2, and KC may be important mediators of the enhanced
inflammatory response observed in lungs from
cftr
/
mice. This is in agreement with the
results obtained after intratracheal instillation of
Pseudomonas-coated agarose beads, where these were the only
inflammatory mediators that demonstrated a statistically significant
increase compared with WT controls (14). However, in that
model, neutrophil levels were minimally increased in
cftr
/
compared with WT mice, whereas
LTB4 and IL-1
levels were markedly increased, although
these differences were not statistically significant. In our model,
LTB4 levels were not different between
cftr
/
and WT mice under these conditions.
Pretreatment of cftr
/
mice with oral DHA did
not significantly decrease TNF-
, MIP-2, or KC levels. Similarly, DHA
administration did not significantly alter MIP-2 and KC levels in WT
mice, although TNF-
levels were statistically decreased. Taken
together, these data indicate that, under the conditions utilized, DHA
treatment does not suppress these proinflammatory cytokines in the
lungs of cftr
/
mice.
Eicosanoids were also examined to determine their role in this
inflammatory process. 6-Keto-PGF1
, PGF2
,
PGE2, and TxB2 levels were elevated in
cftr
/
mice compared with WT control animals,
suggesting that these arachidonic acid metabolites may also play an
important role in the initial stages of the enhanced lung inflammatory
response observed in cftr
/
mice. This is in
agreement with data from other groups demonstrating an increase in
eicosanoids in BAL fluid (19), saliva (22a), and urine (24a) from CF patients. The fact that
pretreatment of cftr
/
mice, but not WT mice,
with oral DHA resulted in suppression of these eicosanoids suggests
that DHA may be reversing a specific abnormality related to CFTR
dysfunction, perhaps related to the abnormality in fatty acid
metabolism. Specifically, the elevated levels of phospholipid-bound
arachidonic acid may be directly responsible for the increased
production of eicosanoids. Administration of oral DHA, by competing for
incorporation at the sn-2 position in membrane phospholipids, decreases
arachidonic acid levels, thereby lowering the production of
eicosanoids. However, the lowering of eicosanoids is not a generalized
phenomena, because LTB4 levels were not affected by oral
administration of DHA in this animal model. Because virtually all cells
can synthesize eicosanoids, it is difficult to identify which cell
type(s) is responsible for the increased levels produced in the lungs
of cftr
/
mice. Outside of LTB4,
there are few studies examining whether other eicosanoids participate
in leukocyte recruitment. Of the four eicosanoids found to be increased
in this model of aerosolized LPS-induced lung inflammation and
specifically suppressed by oral DHA, only PGF2
has been
shown to have potent polymorphonuclear neutrophil chemotactic activity
(1, 15, 24). This was not observed with PGE2
(1), and 6-keto-PGF1
and TxB2
have not been directly tested. These data suggest that the decrease in
neutrophil concentration in BAL fluid after pretreatment of cftr
/
mice with DHA may be, in part,
mediated through a decrease in PGF2
-induced neutrophil
recruitment. Further experiments that use specific inhibitors of
PGF2
may clarify the role of this molecule.
There is increasing evidence that a defect in CFTR function leads to an
exaggerated inflammatory host response in both respiratory epithelial
cells, as well as in lung resident macrophages. This appears to be a
constitutive abnormality, because CF bronchial submucosal glands
cultured from CF patients demonstrate an increase in basal IL-6 and
IL-8 levels compared with non-CF control cells (16, 26).
This increase in IL-8 levels can be explained by significant amounts of
constitutively activated nuclear factor-
B (NF-
B) in these CF cell
lines (9). In addition, human CF bronchial gland cells
display a lack of cytosolic factor I-
B
, also resulting in an
upregulation of IL-8 production compared with non-CF disease bronchial
gland cells (25). These results were confirmed in cultured
human CF bronchial gland cells in which a lack of cytosolic I-
B
and high levels of constitutively activated NF-
B, associated with an
upregulation of IL-8 production, were found compared with non-CF
disease bronchial gland cells. In addition to this increase in these
proinflammatory mediators, IL-10 levels have been reported to be
markedly decreased both in BAL fluid (6) and in isolated bronchial epithelial cells from CF patients (5).
Furthermore, the notion that CFTR mutations predispose to enhanced lung
inflammation is supported by the fact that BAL fluid from CF infants,
before demonstrable colonization or infection occurs, contains higher concentrations of neutrophils and IL-8 compared with BAL fluid from
disease control infants (2, 18).
In an effort to determine whether inflammatory cells in addition to
respiratory epithelial cells are involved in the genesis of this
altered inflammatory response, macrophages from CF patients, both
differentiated in vitro from monocytes (22) and from BAL fluid (6, 18), have been shown to secrete increased levels of IL-8 as well as TNF-
. This is in agreement with the fact that monocytes contain low levels of CFTR based on RT-PCR and southern analysis (27). In the present model, it should be
emphasized that respiratory epithelial cells, in contrast to the
macrophage, minimally respond to bacterial LPS with no stimulation of
IL-8 secretion (10). Therefore, the initial inflammatory
response to LPS is generated by the lung macrophage. Production of
TNF-
and other cytokines by macrophages after exposure to
Pseudomonas LPS may lead to secondary production of
cytokines by respiratory epithelial cells and to an amplification of
the inflammatory response. Whether the increase in TNF-
, MIP-2, and
KC levels in BAL fluid from cftr
/
mice of
observed exposure to Pseudomonas LPS is of macrophage origin, from the respiratory epithelium, or a combination cannot be
ascertained in this model.
An alternative mechanism that would explain our findings of an
exaggerated inflammatory response in CF is a defect in the development
of tolerance to repeated LPS exposure. Endotoxin tolerance was first
described by Beeson (3), who observed a decrease in
febrile response after repeated injection of rabbits with endotoxin, and appears to be a protective mechanism to prevent uncontrolled immunological activation in the host after septicemia that could lead
to continuous production of proinflammatory cytokines, such as TNF-
,
and to severe vascular collapse (29). The principal cells
responsible for the development of this tolerance effect are monocytes
and macrophages (12). This effect is not secondary to a
decrease in CD14, the LPS receptor on the cell surface of these cells,
but perhaps is due to a formation of inactive NF-
B complexes
consisting of p50 homodimers (4). Alternatively, tolerance
may result from the downregulation of IL-12 secretion observed after
chronic exposure of human monocytes to LPS in culture (17). Taken together, these data would be consistent with
the notion that the development of endotoxin tolerance is defective in
CF and perhaps DHA modulates this tolerance mechanism. Further experiments are required to determine the validity of this hypothesis in cftr
/
mice.
Our previous data indicate that a membrane lipid imbalance is present
in ileum, pancreas, and lung from cftr
/
mice, characterized by a selective increase in phospholipid-bound arachidonic acid and a decrease in phospholipid-bound DHA
(11). Treatment of these mice with oral DHA resulted in
correction of the lipid abnormality as well as reversal of the
pathology in pancreas and ileum. Although the effects of DHA on
suppression of TNF, MIP-2, and KC levels in BAL fluid were similar in
both WT and cftr
/
mice exposed to
Pseudomonas LPS, the fact that neutrophils and the
eicosanoids studied were decreased only in
cftr
/
mice but not WT animals suggests that
the membrane lipid imbalance observed in lungs from
cftr
/
mice may play an important role in the
pathogenesis of this enhanced pulmonary inflammation.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Rene Mora from the Department of Medicine at Beth Israel Deaconess Medical Center for help in setting up the Pseudomonas LPS nebulizer apparatus. We also thank Dr. Christopher Karp from the Department of Infectious Diseases at The Johns Hopkins University for critical review of this manuscript.
| |
FOOTNOTES |
|---|
This work was supported by the Cystic Fibrosis Foundation (J. G. Alvarez and S. D. Freedman) and by National Institutes of Health Grants GM-15431, DK-48831, and CA-77839 (to J. D. Morrow). J. D. Morrow is also the recipient of a Burroughs Wellcome Fund Clinical Scientist Award in Translational Research.
Address for reprint requests and other correspondence: S. D. Freedman, Beth Israel Deaconess Medical Center, Dana 532, 330 Brookline Ave., Boston, MA 02215 (E-mail: sfreedma{at}caregroup.harvard.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published January 11, 2002;10.1152/japplphysiol.00927.2001
Received 6 September 2001; accepted in final form 9 January 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Arnould, T,
Thibaut-Vercruyssen R,
Bouaziz N,
Dieu M,
Remacle J,
and
Michiels C.
PGF2
, a prostanoid released by endothelial cells activated by hypoxia, is a chemoattractant candidate for neutrophil recruitment.
Am J Pathol
159:
345-357,
2001.
2.
Balough, K,
McCubbin M,
Weinberger M,
Smits W,
Ahrens R,
and
Fick R.
The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis.
Pediatr Pulmonol
20:
63-70,
1995.
3.
Beeson, PB.
Tolerance to bacterial pyrogens. I. Factors influencing its development.
J Exp Med
86:
29-44,
1947.
4.
Bohuslav, J,
Kravchenko VV,
Parry GC,
Erlich JH,
Gerondakis S,
Mackman N,
and
Ulevitch RJ.
Regulation of an essential innate immune response by the p50 subunit of NF-
B.
J Clin Invest
102:
1645-1652,
1998.
5.
Bonfield, TL,
Konstan MW,
and
Berger M.
Altered respiratory epithelial cell cytokine production in cystic fibrosis.
J Allergy Clin Immunol
104:
72-78,
1999.
6.
Bonfield, TL,
Panuska JR,
Konstan MW,
Hilliard KA,
Hilliard JB,
Ghnaim H,
and
Berger M.
Inflammatory cytokines in cystic fibrosis lungs.
Am J Respir Crit Care Med
152:
2111-2118,
1995.
7.
Coffey, RJ,
Hawkey CJ,
Damstrup L,
Graves-Deal R,
Daniel VC,
Dempsey PJ,
Chinery R,
Kirkland SC,
DuBois RN,
Jetton TL,
and
Morrow JD.
Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells.
Proc Natl Acad Sci USA
94:
657-662,
1997.
8.
Davidson, DJ,
Dorin JR,
McLachlan G,
Ranaldi V,
Lamb D,
Doherty C,
Govan J,
and
Porteous DJ.
Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens.
Nat Genet
9:
351-357,
1995.
9.
DiMango, E,
Ratner AJ,
Bryan R,
Tabibi S,
and
Prince A.
Activation of NF-
B by adherent Psuedomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells.
J Clin Invest
101:
2598-2605,
1998.
10.
DiMango, E,
Zar HJ,
Bryan R,
and
Prince A.
Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8.
J Clin Invest
96:
2204-2210,
1995.
11.
Freedman, SD,
Katz MH,
Parker EM,
Laposata M,
Urman MY,
and
Alvarez JA.
A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr
/
mice.
Proc Natl Acad Sci USA
96:
13995-14000,
1999.
12.
Freudenber, MD,
and
Galanos C.
Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages.
Infect Immun
56:
1352-1357,
1988.
13.
Gosselin, D,
Stevenson MM,
Cowley EA,
Griesenbach U,
Eidelman DH,
Boule M,
Tam MF,
Kent G,
Skamene E,
Tsui LC,
and
Radzioch D.
Impaired ability of Cftr knockout mice to control lung infection with Pseudomonas aeruginosa.
Am J Respir Crit Care Med
157:
1253-1262,
1998.
14.
Heeckeren, A,
Walenga R,
Konstan MW,
Bonfield T,
Davis PB,
and
Ferkol T.
Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa.
J Clin Invest
100:
2810-2815,
1997.
15.
Hoedemaker, M,
Lund LA,
and
Wagner WC.
Influence of arachidonic acid metabolites and steroids on function of bovine polymorphonuclear neutrophils.
Am J Vet Res
53:
1534-1539,
1992.
16.
Kammouni, W,
Figarella C,
Marchand S,
and
Merten M.
Altered cytokine production by cystic fibrosis tracheal gland serous cells.
Infect Immun
65:
5176-5183,
1997.
17.
Karp, CL,
Wysocka M,
Ma X,
Marovich M,
Factor RE,
Nutman T,
Armant M,
Wahl L,
Cuomo P,
and
Trinchieri G.
Potent suppression of IL-12 production from monocytes and dendritic cells during endotoxin tolerance.
Eur J Immunol
28:
3128-3136,
1998.
18.
Khan, TZ,
Wagener JS,
Bost T,
Martinez J,
Accurso FJ,
and
Riches DWH
Early pulmonary inflammation in infants with cystic fibrosis.
Am J Respir Crit Care Med
151:
1075-1082,
1995.
19.
Kostan, MW,
Walenga RW,
Hillard KA,
and
Hillard JB.
Leukotriene B4 is markedly elevated in the epithelial lining fluid of patients with cystic fibrosis.
Am Rev Respir Dis
148:
896-901,
1993.
20.
Muhlebach, M,
Stewart P,
Leigh M,
and
Noah T.
Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients.
Am J Respir Crit Care Med
160:
186-191,
1999.
21.
Noah, TL,
Black HR,
Cheng PW,
Wood RE,
and
Leigh MW.
Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis.
J Infect Dis
175:
638-647,
1997.
22.
Pfeffer, KD,
Huecksteadt TP,
and
Hoidal JR.
Expression and regulation of tumor necrosis factor in macrophages from cystic fibrosis patients.
Am J Respir Cell Mol Biol
9:
511-519,
1993.
22a.
Rigas, B,
Korenberg JR,
Merrill WW,
and
Levine L.
Prostaglandins E2 and F2
are elevated in saliva of cystic fibrosis patients.
Am J Gastroenterol
84:
1408-1412,
1989.
23.
Riordan, JR,
Rommens JM,
Kerem BS,
Alon N,
Rozmahel R,
Grzelczak Z,
Zielenski J,
Lok S,
Plavsic N,
Chou JL,
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.
Science
245:
1066-1073,
1989.
24.
Roch-Arveiller, M,
Drouin JY,
Puisieux F,
and
Giroud JP.
Direct identification of a chemoattractant by a visual assay.
Blood Cells
10:
129-133,
1984.
24a.
Strandvik, B,
Svensson E,
and
Seyberth HW.
Prostanoid biosynthesis in patients with cystic fibrosis.
Prostaglandins Leukot Essent Fatty Acids
55:
419-425,
1996.
25.
Tabary, O,
Escotte S,
Couetil JP,
Hubert D,
Dusser D,
Puchelle E,
and
Jacquot J.
Genistein inhibits constitutive and inducible NFkB activation and decreases IL-8 production by cystic bronchial gland cells.
Am J Pathol
155:
473-481,
1999.
26.
Tabary, O,
Zahm JM,
Hinnrasky J,
Couetil JP,
Cornillet P,
Guenounou M,
Gaillard D,
Puchelle E,
and
Jacquot J.
Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro.
Am J Pathol
153:
921-930,
1998.
26a.
Thomas, GR,
Costelloe EA,
Lunn DP,
Stacey KJ,
Delaney SJ,
Passey R,
McGlinn EC,
McMorran BJ,
Ahadizadeh A,
Geczy CL,
Wainwright BJ,
and
Hume DA.
G551D Cystic fibrosis mice exhibit abnormal regulation of inflammation in lungs and macrophages.
J Immunol
164:
3870-3877,
2000.
27.
Yoshimura, K,
Nakamura H,
Trapnell BC,
Chu CS,
Dalemans W,
Pavirani A,
Lecocq JP,
and
Crystal RG.
Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin.
Nucleic Acids Res
19:
5417-5423,
1991.
28.
Zeng, W,
Lee MG,
Yan M,
Diaz J,
Benjamin I,
Marino CR,
Kopito R,
Freedman S,
Cotton C,
Muallem S,
and
Thomas P.
Immuno and functional characterization of CFTR in submandibular and pancreatic acinar and duct cells.
Am J Physiol Cell Physiol
273:
C442-C455,
1997.
29.
Ziegler-Heitbrock, HWL
Molecular mechanism to tolerance to lipopolysaccharide.
J Inflamm
45:
13-26,
1995.
This article has been cited by other articles:
![]() |
E. M. Bruscia, P.-X. Zhang, E. Ferreira, C. Caputo, J. W. Emerson, D. Tuck, D. S. Krause, and M. E. Egan Macrophages Directly Contribute to the Exaggerated Inflammatory Response in Cystic Fibrosis Transmembrane Conductance Regulator-/- Mice Am. J. Respir. Cell Mol. Biol., March 1, 2009; 40(3): 295 - 304. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Bartling and M. L. Drumm Oxidative Stress Causes IL8 Promoter Hyperacetylation in Cystic Fibrosis Airway Cell Models Am. J. Respir. Cell Mol. Biol., January 1, 2009; 40(1): 58 - 65. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tiesset, M. Pierre, J.-L. Desseyn, B. Guery, C. Beermann, C. Galabert, F. Gottrand, and M.-O. Husson Dietary (n-3) Polyunsaturated Fatty Acids Affect the Kinetics of Pro- and Antiinflammatory Responses in Mice with Pseudomonas aeruginosa Lung Infection J. Nutr., January 1, 2009; 139(1): 82 - 89. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Andersson, M. R. Al-Turkmani, J. E. Savaille, R. Alturkmani, W. Katrangi, J. E. Cluette-Brown, M. M. Zaman, M. Laposata, and S. D. Freedman Cell culture models demonstrate that CFTR dysfunction leads to defective fatty acid composition and metabolism J. Lipid Res., August 1, 2008; 49(8): 1692 - 1700. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Perez, A. M. van Heeckeren, D. Nichols, S. Gupta, J. F. Eastman, and P. B. Davis Peroxisome proliferator-activated receptor-{gamma} in cystic fibrosis lung epithelium Am J Physiol Lung Cell Mol Physiol, August 1, 2008; 295(2): L303 - L313. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Saadane, S. Masters, J. DiDonato, J. Li, and M. Berger Parthenolide Inhibits I{kappa}B Kinase, NF-{kappa}B Activation, and Inflammatory Response in Cystic Fibrosis Cells and Mice Am. J. Respir. Cell Mol. Biol., June 1, 2007; 36(6): 728 - 736. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. White, D. Jiang, J. D. Burgess, I. R. Bederman, S. F. Previs, and T. J. Kelley Altered cholesterol homeostasis in cultured and in vivo models of cystic fibrosis Am J Physiol Lung Cell Mol Physiol, February 1, 2007; 292(2): L476 - L486. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Guilbault, Z. Saeed, G. P. Downey, and D. Radzioch Cystic Fibrosis Mouse Models Am. J. Respir. Cell Mol. Biol., January 1, 2007; 36(1): 1 - 7. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Tabary, H. Corvol, E. Boncoeur, K. Chadelat, C. Fitting, J. M. Cavaillon, A. Clement, and J. Jacquot Adherence of airway neutrophils and inflammatory response are increased in CF airway epithelial cell-neutrophil interactions Am J Physiol Lung Cell Mol Physiol, March 1, 2006; 290(3): L588 - L596. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. G. Blanco, M. M. Zaman, O. Junaidi, S. Sheth, R. K. Yantiss, I. A. Nasser, and S. D. Freedman Induction of colitis in cftr-/- mice results in bile duct injury Am J Physiol Gastrointest Liver Physiol, August 1, 2004; 287(2): G491 - G496. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Freedman, P. G. Blanco, M. M. Zaman, J. C. Shea, M. Ollero, I. K. Hopper, D. A. Weed, A. Gelrud, M. M. Regan, M. Laposata, et al. Association of Cystic Fibrosis with Abnormalities in Fatty Acid Metabolism N. Engl. J. Med., February 5, 2004; 350(6): 560 - 569. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. N. Serhan, S. Hong, K. Gronert, S. P. Colgan, P. R. Devchand, G. Mirick, and R.-L. Moussignac Resolvins: A Family of Bioactive Products of Omega-3 Fatty Acid Transformation Circuits Initiated by Aspirin Treatment that Counter Proinflammation Signals J. Exp. Med., October 21, 2002; 196(8): 1025 - 1037. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |